Absence of Alleviates Negative Growth Effects of Colistin Resistance in .
Jessie E Wozniak, Aroon T Chande, Eileen M Burd, Victor I Band, Sarah W Satola, Monica M Farley, Jesse T Jacob, I King Jordan, David S Weiss
Author Information
Jessie E Wozniak: Emory Vaccine Center, Atlanta, GA 30317, USA.
Aroon T Chande: Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA 30332, USA. ORCID
Eileen M Burd: School of Medicine, Emory University, Atlanta, GA 30322, USA. ORCID
Victor I Band: Emory Vaccine Center, Atlanta, GA 30317, USA.
Sarah W Satola: School of Medicine, Emory University, Atlanta, GA 30322, USA.
Monica M Farley: School of Medicine, Emory University, Atlanta, GA 30322, USA.
Jesse T Jacob: School of Medicine, Emory University, Atlanta, GA 30322, USA. ORCID
I King Jordan: School of Biological Sciences, Georgia Institute of Technology, Atlanta, GA 30332, USA.
David S Weiss: Emory Vaccine Center, Atlanta, GA 30317, USA.
中文译文
English
Colistin is an important last-line antibiotic to treat highly resistant infections. Resistance to colistin has emerged among clinical isolates but has been associated with a significant growth defect. Here, we describe a clinical isolate with a deletion of , a regulator of colistin resistance, leading to high-level resistance in the absence of a growth defect. The identification of a path to resistance unrestrained by growth defects suggests colistin resistance could become more common in .
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
[PMID: 28375512 ]
PLoS One. 2010 Oct 08;5(10):e13244
[PMID: 20949038 ]
Microb Drug Resist. 2018 Oct;24(8):1117-1120
[PMID: 29768099 ]
Int J Antimicrob Agents. 2020 Apr;55(4):105930
[PMID: 32130981 ]
Antimicrob Agents Chemother. 2015 May;59(5):2898-900
[PMID: 25691629 ]
J Antimicrob Chemother. 2015 Jan;70(1):75-80
[PMID: 25190723 ]
Antimicrob Agents Chemother. 2020 May 21;64(6):
[PMID: 32253218 ]
J Bacteriol. 2010 May;192(9):2463-4
[PMID: 20207761 ]
Mol Microbiol. 2019 Jun;111(6):1604-1616
[PMID: 30873646 ]
Antimicrob Agents Chemother. 2015 Oct 12;60(1):609-12
[PMID: 26459897 ]
J Antimicrob Chemother. 2018 Jun 1;73(6):1604-1610
[PMID: 29514208 ]
Infect Control Hosp Epidemiol. 2019 Jan;40(1):112-113
[PMID: 30463634 ]
Sci Rep. 2016 May 06;6:25543
[PMID: 27150578 ]
N Engl J Med. 2014 Mar 27;370(13):1198-208
[PMID: 24670166 ]
Curr Opin Microbiol. 2014 Feb;17:106-13
[PMID: 24531506 ]
Antimicrob Agents Chemother. 2014 Oct;58(10):5696-703
[PMID: 25022583 ]
Mol Microbiol. 2016 Nov;102(3):430-445
[PMID: 27447896 ]
Genome Biol. 2004;5(2):R12
[PMID: 14759262 ]
PLoS Genet. 2009 Dec;5(12):e1000788
[PMID: 20041203 ]
Mol Syst Biol. 2006;2:2006.0008
[PMID: 16738554 ]
Nat Microbiol. 2016 May 09;1(6):16053
[PMID: 27572838 ]
Nat Microbiol. 2018 May;3(5):563-569
[PMID: 29693659 ]
J Glob Antimicrob Resist. 2020 Jun;21:386-390
[PMID: 31838239 ]
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6640-5
[PMID: 10829079 ]
Int J Mol Sci. 2019 Apr 10;20(7):
[PMID: 30974906 ]
J Bacteriol. 1995 Aug;177(15):4364-71
[PMID: 7543474 ]
J Bacteriol. 2001 Mar;183(6):1835-42
[PMID: 11222580 ]
J Antimicrob Chemother. 2015 Aug;70(8):2261-70
[PMID: 26017037 ]
Antimicrob Agents Chemother. 2014;58(1):518-26
[PMID: 24189257 ]
P51 OD011132/NIH HHS
R01 AI141883/NIAID NIH HHS
David S. Weiss/Burroughs Wellcome Fund
AI141883/NIH HHS